Mirum Pharmaceuticals Stock Decline Follows Q4 Earnings and Share Offering

Mirum Pharmaceuticals (MIRM) stock experienced a significant drop on February 26, 2026, falling 15.1% to close at $92 per share. This decline followed the release of the company’s fourth-quarter earnings report and the announcement of a share offering, which introduced potential dilution for investors.

Q4 2025 Financial Performance

Despite the stock’s downturn, Mirum Pharmaceuticals reported positive growth in its Q4 2025 net product sales, which rose 49.8% to $148.9 million, according to Reuters. The company similarly noted an increase in overall sales for the year 2025. However, the announcement of a potential offering of up to 8.96 million shares by selling stockholders overshadowed these gains, leading to investor concerns about dilution.

2026 Outlook and Projections

Mirum had previously projected global net product sales of up to $650 million for 2026. While the company demonstrates commercial momentum, investors are currently prioritizing the potential impact of the share offering on the stock’s valuation.

Company Overview and Pipeline

Mirum Pharmaceuticals is a biotechnology company specializing in the development and commercialization of treatments for rare liver diseases. Its key products include LIVMARLI, approved for cholestatic pruritus in Alagille syndrome, as well as Cholbam and Chenodal. The company recently completed the acquisition of Bluejay Therapeutics and received Health Canada authorization for LIVMARLI in PFIC and Alagille syndrome, signaling pipeline expansion.

Financial Position

As of late 2025, Mirum maintains a net cash position, with net debt at negative $63.9 million and a net debt to EBITDA ratio of -14.2x. The company’s enterprise value is $5.5 billion, compared to a market capitalization of $5.6 billion. The stock’s 5-year beta is 0.50, indicating relatively lower volatility compared to other biotechnology companies.

Analyst Perspective

Despite the recent decline, Mirum’s stock remains well above its 52-week low of $37, with analysts maintaining a price target of $120. However, secondary offerings can often trigger significant market reactions as investors reassess valuations in response to increased supply.

Investor Resources

Investors interested in a deeper analysis of Mirum Pharmaceuticals’ financials and growth potential can utilize resources like TIKR to access historical data, analyst forecasts, and valuation multiples. TIKR provides tools for tracking stocks and evaluating investment opportunities.

Disclaimer: This article is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.